Cancer/Chemo Flashcards
Chemo man N
Nitrosoureas (Carmustine)
Neurotoxic (crosses the BBB)
Chemo man C
Cisplatin, Carboplatin
Nephro/ototoxic
Chemo man V
Vinca Alkaloid (Vincristine, Vinblastine) Peripheral neuropathy
Chemo man B
Bleomycin, Busulfan
Pulmonary fibrosis
Chemo man D
Doxorubicin
Cardiotoxic
Chemo man P
CycloPhosphamide
Hemorrhagic cystitis
Chemo man MF
Methotrexate and 5-Fluorouracil
Myelosuppression
Max benefits of chemo
Intermittent chemo
Combo chemo
Dosing schedule
Drug delivery
Tumor lysis syndrome
From destruction of cells causing hyperuricemia which causes AKI
Increased K, Phosphorus
Decreased Ca
Alkylating Drugs
Cyclophosphamide
Carmustine
Nitrogen mustard Drug
Cyclophosphamide
Cyclophosphamide MOA
Cell kill results primarily from alkylation of DNA
Toxic tissue that have growth fraction
Cross links with DNA and prevents replication
Disrupts DNA/RNA synthesis
Cyclophosphamide Use
Broad spectrum Hodgkins, Non hodgkins MM Solid tumors RA MS
Cyclophosphamide Route
IV
PO - Give with food
Cyclophosphamide A/E
Severe nausea Vomiting Alopecia Acute hemorrhagic cystitis Vesicant
Cyclophosphamide Dose limiting toxicity
Bone marrow suppression
Cyclophosphamide Pt edu
Mesna is often used to protect the bladder
Need to increase fluids and urination
Cyclophosphamide Nursing considerations
Conversion to active form in the liver
Resistance is common
Give antiemetic daily
Nitrosoureas Drug
Carmustine
Carmustine MOA
Cell kill results primarily from alkylation of DNA
Toxic tissue that have growth fraction
Cross links with DNA and prevents replication
Crosses the BBB
Carmustine Use
Primary metastatic brain cancer Hodgkins, Non hodgkins MM Malignant melanoma Hepatoma Adenocarcinoma
Carmustine Route
Topical (wafer that is often placed where the tumor is on the brain and slowly dissolves and destroys the tumor)
IV
Carmustine A/E
Severe N/V
Injury to liver and kidneys
Pulmonary fibrosis (cumulative high doses)
Carmustine Dose limiting toxicity
Delayed bone marrow suppression (4-6wk)
Carmustine Monitoring
CBC (bone marrow suppression)
Vitals
Carmustine Baseline information
LFT
BUN
Cr
Platinum Compound Drug
Cisplatin
Cisplatin MOA
Produces cross links to DNA
Cell cycle phase non specifc
Kills cells by forming cross links between and within strands of DNA
Cisplatin Use
Metastatic testicular and ovarian cancers
Advanced bladder cancer
Cisplatin Route
IV
Cisplatin A/E
Highly emetogenic (severe N/V) Peripheral neuropathy (years later) Bone marrow suppression (mild to moderate) Ototoxic Vesicant
Cisplatin Dose limiting toxicity
Kidney damage (might need a diuretic)
Cisplatin Monitoring
I/O
BUN
Cr
Antimetabolites Folic acid analog
Methotrexate
Methotrexate MOA
Blocks the conversion of folic acid to its active form
S phase specific
Methotrexate Use
Non-hodgkin's Leukemia Head/Neck Crosses BBB RA Crohn's
Methotrexate A/E
N/V Fetal malformation/death Pulmonary infiltrates, fibrosis Oral/GI ulcerations Kidney injury
Methotrexate Contraindications
Pregnancy +6mo after
Methotrexate dose limiting toxicity
Bone marrow suppression
Methotrexate Nursing considerations
Leucovorin rescue
↳helps prevent kidney damage, alkalize urine, promote excretion
↳given 24hr after meth is given
Must have negative pregnancy test done before
Hydrate very well
Give Sodium bicarbonate to alkalize the urine
Antimetabolites Pyrimidine analog Drug
Fluorouracil (5-Fluorouracil/ 5FU)
Fluorouracil MOA
Inhibits thymidylate synthase depriving cells of thymidylate needed to make DNA
S phase specific
Fluorouracil Use
Solid tumors (colorectal) DOC: Skin cancer due to topical use
Fluorouracil Route
Continuous IV
Fluorouracil A/E
Alopecia
Cognitive impairment
Hyperpigmentation
Fluorouracil Dose limiting toxicity
Bone marrow suppression (neutropenia)
Oral/GI ulcerations/ Diarrhea (D/C as soon as they occur)
Hand/ Foot syndrome (give uridine triacetate- antidote)
Antimetabolite Purine analog Drug
Mercaptopurine
Mercaptopurine MOA
Disrupts purine biosynthesis, nucleotide conversion, and biosynthesis of nucleic acid
S phase specific
Mercaptopurine Use
Maintenance acute lymphocytic leukemia
Mercaptopurine Route
PO
Mercaptopurine Dose limiting toxicity
Bone marrow suppression
Hepatotoxic